|Table of Contents|

Diagnosis and treatment of pulmonary embolism of postoperative complications for gynecologic oncology:A report of four cases

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 05
Page:
841-844
Research Field:
Publishing date:

Info

Title:
Diagnosis and treatment of pulmonary embolism of postoperative complications for gynecologic oncology:A report of four cases
Author(s):
ZHAO Shuahua; SHI Yuan; LYU Xiaohui; GUO Qian; LIU Shujuan; WANG Jian; YANG Hong
Department of Obstetrics and Gynaecology，Xijing Hospital，Air Force Medical University，Shaanxi Xi＇an 710032，China.
Keywords:
gynecologic tumor; pulmonary embolism; anticoagulation therapy
PACS:
R737.3
DOI:
DOI:10.3969/j.issn.1672-4992.2021.05.026
Abstract:
Objective:To investigate the clinical features and strategies of diagnosis and treatments of pulmonary embolism of postoperative complications for gynecologic oncology.Methods:Clinical data,diagnosis and treatment methods and prognosis of 4 patients with pulmonary embolism after gynecological tumor surgery admitted to Xijing Hospital of Air Force Medical University from January 2019 to October 2019 were retrospectively analyzed.Results:All 4 patients admitted were diagnosed with pulmonary embolism within 2~4 days after surgery,which presented with varying degrees of dyspnea,chest tightness,shortness of breath,cough and lethargy.The patient was referred to the anesthesia intensive care unit （ICU）after operation,and then administered rivaroxaban for peroral medication,after 20 days of warfarin and nadroparin calcium anticoagulant therapy.The remaining patients （3 patients）were treated with oral medication,such as rivaroxaban.All 4 patients were followed up in good condition.Conclusion:The Gold Standard in the diagnosis of pulmonary embolism （PE）is computerized tomography pulmonary angiography（CTPA）,and oral anticoagulant is an effective method for the treatment of PE.Improving the prevention of pulmonary embolism by obstetricians and gynecologists after gynecologic tumor surgery can reduce the mortality rate of patients,and early detection,diagnosis and treatment are crucial to improve the prognosis of patients.

References:

［1］李晓强,张福先,王深明.深静脉血栓形成的诊断和治疗指南［J］．中国血管外科杂志（电子版），2017,9(4):250-257. LI XQ,ZHANG FX,WANG SM.Diagnosis and treatment of deep vein thrombosis［J］.Chinese Journal of Vascular Surgery,2017,9(4):250-257.
[2]KHORANA AA,DALAL M,LIN J,et al.Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States［J］.Cancer,2013,119(3):648-655.
[3]CLAGETT GP,REISCH JS.Prevention of venous thromboembolism in general surgical patients:Results of meta-analysis［J］.Annals of Surgery,1988,208(2):227-420.
[4]PEZZUOLI G,NERI SERNERI GG,SETTEMBRINI P,et al.Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216:A multicentre,double-blind,randomized,controlled,clinical trial versus placebo (STEP).STEP-study group［J］.Int Surg,1989,74(4):205-210.
[5]MISMETTI P,LAPORTE S,DARMON JY,et al.Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery［J］.Br J Surg,2001,88(7):913-390.
[6]RASKOB GE,ANGCHAISUKSIRI P,BLANCO AN,et al.Thrombosis:A major contributor to global disease burden(review)［J］.Arterioscler Thromb Vasc Biol,2014,34(11):2363-2371.
[7]王春艳,金时,孟庆威, 等.肺癌静脉血栓栓塞的危险因素及生物标志物的研究进展［J］．现代肿瘤医学,2018,26(06):958-962. WANG CY,JIN S,MENG QW,et al.Venous thromboembolism and lung cancer:A systematic review in risk factors and biomarkers［J］．Modern Oncology,2018,26(06):958-962.
[8]HUANG W,GOLDBERG RJ,ANDERSON FA,et al.Secular trends in occurrence of acute venous thromboembolism:The Worcester VTE study (1985-2009)［J］.Am J Med,2014,127(9):829-839.
[9]ZENG QJ,TAN SF,BAO Q,et al.Intra-operative blood transfusion significantly increases the risk of post-operative pulmonary embolism［J］.Journal of Thoracic Disease,2019,11(12):5566-5571.
[10]ABU-RUSTUM NR,RICHARD S,WILTON A,et al.Transfusion utilization during adnexal or peritoneal cancer surgery:Effects on symptomatic venous thromboembolism and survival［J］.Gynecol Oncol,2005,99:320-326.
[11]ROGERS SO JR,KILARU RK,HOSOKAWA P,et al.Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery:Results from the patient safety in surgery study［J］.J Am Coll Surg,2007,204(6):1211-1221.
[12]XENOS ES,VARGAS HD,DAVENPORT DL.Association of blood transfusion and venous thromboembolism after colorectal cancer resection［J］.Thromb Res,2012,129(5):568-572.
[13]HEIT JA.Epidemiology of venous thromboembolism［J］.Nat Rev Cardiol,2015,12(8):464-474.
[14]STEIN PD,MATTA F,MUSANI MH,et al.Silent pulmonary embolism in patients with deep venous thrombosis:A systematic review［J］.Am J Med,2010,123(5):426-431.
[15]WIENER RS,SCHWARTZ LM,WOLOSHIN S.When a test is too good:How CT pulmonary angiograms find pulmonary emboli that do not need to be found［J］.BMJ,2013,347:1756-1833.
[16]ERKENS PM,PRINS MH.Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism［J］.Cochrane Database Syst Rev,2010,8(9):CD001100.
[17]CASTELLUCCI LA, CAMERON C, LE GAL G, et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism:A systematic review and meta-analysis［J］. JAMA, 2014,312(11): 1122-1135.
[18]HEIDBUCHEL H, VERHAMME P, ALINGS M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation［J］. Europace, 2015, 17(10): 1467-1507.
[19]VAN ES N, COPPENS M, SCHULMAN S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: Evidence from phase 3 trials［J］. Blood,2014,124(12): 1968-1975.
[20]KEARON C, AKL EA, ORNELAS J, et al. Antithrombotic therapy for VTE disease: Chest Guideline and Expert Panel Report［J］. Chest, 2016,149(2): 315-352.
[21]BEYER-WESTENDORF J, AGENO W. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism［J］. Thromb Haemost,2015,113(2): 231-246.
[22]AGENO W, MANTOVANI LG, HAAS S, et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): An international, prospective, non-interventional study［J］. Lancet Haematol, 2016,3(1): e12-e21.
[23]AUJESKY D, ROY PM, VERSCHUREN F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: An international, open-label, randomised, non-inferiority trial［J］. Lancet,2011,378(9785): 41-48.
[24]OST D, TEPPER J, MIHARA H, et al. Duration of anticoagulation following venous thromboembolism: A meta-analysis［J］. JAMA, 2005,294(6): 706-715.
[25]KEARON C, GENT M, HIRSH J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism［J］. N Engl J Med, 1999,340(12): 901-907.
[26]LINKINS LA, CHOI PT, DOUKETIS JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism:A meta-analysis［J］. Ann Intern Med, 2003, 139(11): 893-900.
[27]BAGLIN T, BAUER K, DOUKETIS J, et al. Duration of anticoagulant therapy after a fi rst episode of an unprovoked pulmonary embolus or deep vein thrombosis:Guidance from the SSC of the ISTH［J］. J Thromb Haemost, 2012,10(4): 698-702.

Memo

Memo:
陕西省社会发展科技攻关项目（编号：2016SF-254）；西京医院学科助推计划基金(编号：XJZT18MJ92)
Last Update: 2021-01-29